Log in to save to my catalogue

Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from cli...

Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from cli...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b004166f59b241048d489a487c035582

Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

About this item

Full title

Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

Publisher

Milan: Springer Milan

Journal title

Journal of headache and pain, 2023-11, Vol.24 (1), p.157-157, Article 157

Language

English

Formats

Publication information

Publisher

Milan: Springer Milan

More information

Scope and Contents

Contents

Background
Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population observed in real-world setting. To describe the long-term effectiveness and tolerability of galcanezumab in clinical practice in...

Alternative Titles

Full title

Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_b004166f59b241048d489a487c035582

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b004166f59b241048d489a487c035582

Other Identifiers

ISSN

1129-2377,1129-2369

E-ISSN

1129-2377

DOI

10.1186/s10194-023-01690-2

How to access this item